Amarin Corporation PLC (NASDAQ:AMRN)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Thursday. They currently have a $10.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s target price would suggest a potential upside of 177.78% from the company’s current price.

A number of other brokerages have also recently issued reports on AMRN. BidaskClub cut Amarin Corporation PLC from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine cut Amarin Corporation PLC from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. Jefferies Group LLC reiterated a “buy” rating and set a $7.00 price objective on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. Cantor Fitzgerald reiterated a “buy” rating and set a $10.00 price objective on shares of Amarin Corporation PLC in a research note on Tuesday, September 26th. Finally, Zacks Investment Research upgraded Amarin Corporation PLC from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research note on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $7.75.

Amarin Corporation PLC (NASDAQ:AMRN) traded up $0.04 during trading hours on Thursday, reaching $3.60. The company’s stock had a trading volume of 1,360,000 shares, compared to its average volume of 1,340,000. Amarin Corporation PLC has a 52-week low of $2.76 and a 52-week high of $4.47. The company has a debt-to-equity ratio of -1.48, a current ratio of 1.63 and a quick ratio of 1.46.

Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $47.10 million for the quarter, compared to analyst estimates of $45.85 million. During the same period last year, the company earned ($0.08) EPS. The company’s revenue was up 45.4% compared to the same quarter last year. sell-side analysts forecast that Amarin Corporation PLC will post -0.2 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/hc-wainwright-reiterates-buy-rating-for-amarin-corporation-plc-amrn/1678886.html.

In related news, insider Steven B. Ketchum sold 63,479 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 3.72% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in Amarin Corporation PLC by 348.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,730,200 shares of the biopharmaceutical company’s stock valued at $5,537,000 after acquiring an additional 1,344,200 shares during the period. Morgan Stanley increased its position in Amarin Corporation PLC by 119.7% during the 1st quarter. Morgan Stanley now owns 1,138,992 shares of the biopharmaceutical company’s stock worth $3,645,000 after buying an additional 620,577 shares during the period. UBS Group AG increased its position in Amarin Corporation PLC by 7.4% during the 1st quarter. UBS Group AG now owns 731,518 shares of the biopharmaceutical company’s stock worth $2,341,000 after buying an additional 50,200 shares during the period. California Public Employees Retirement System increased its position in Amarin Corporation PLC by 13.3% during the 1st quarter. California Public Employees Retirement System now owns 533,300 shares of the biopharmaceutical company’s stock worth $1,707,000 after buying an additional 62,800 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Amarin Corporation PLC by 0.9% during the 1st quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock worth $1,266,000 after buying an additional 3,413 shares during the period. Institutional investors and hedge funds own 37.76% of the company’s stock.

About Amarin Corporation PLC

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.